Cogent Biosciences (COGT) Change in Accured Expenses (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Change in Accured Expenses data on file, last reported at -$10.2 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 17.81% year-over-year to -$10.2 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 34.77% decrease from a year earlier, with the FY2025 full-year figure at $10.7 million, down 33.03% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$10.2 million, down from $9.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for COGT reached as high as $10.1 million in Q2 2024 and fell as low as -$10.2 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of $3.0 million in 2022.
• Across the five-year window, Change in Accured Expenses sank 1384.92% in 2023 and jumped 446.08% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.8 million in 2022, then plunged by 30.93% to $2.6 million in 2023, then soared by 115.41% to $5.7 million in 2024, then jumped by 60.75% to $9.1 million in 2025, then plunged by 212.09% to -$10.2 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$10.2 million in Q1 2026, $9.1 million in Q4 2025, and $4.6 million in Q3 2025.